VERV

Verve Therapeutics, Inc.

7.38 USD
+0.22 (+3.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Verve Therapeutics, Inc. stock is up 40.04% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 July’s closed higher than June. In the last 1 Unusual Options Trades, there were 1 CALL.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
11 Jun 19:23 21 Jun, 2024 2.50 CALL 87 1

About Verve Therapeutics, Inc.

Verve Therapeutics, Inc. engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.